20:28:08 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.

Kalender

2023-04-17 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50
2020-11-03 10:04:07
Oslo 03.11.2020 

The project is a research and development collaboration between SoftOx Solutions
AS and leading US and European wound care clinics, focusing on chronic wounds
and biofilm infections. The project represents an innovative treatment principle
in how to prevent and treat biofilm infections in wounds. The grant will
contribute to perform clinical investigations to evaluate the SoftOx technology
in humans with serious non-healing wounds.
 
The award was issued on behalf of the Naval Medical Research Center (NMRC) under
Medical Technology Enterprise Consortium (MTEC) a biomedical technology
consortium that collaborates under a transaction agreement (OTA) with the US
Army Medical Research and Development Command (USAMRDC). The award issued is
entitled “Clinical Development of a New Antimicrobial Agent to Treat and Prevent
Biofilm Formation in Wounds”. SoftOx considers it a great honor that one of the
world’s leading research organizations supports the development and the
technology of SoftOx by issuing the award.

About SoftOx Solutions
SoftOx Solutions AS (SoftOx, listed at Oslo Stock Exchange Merkur Market) is a
Norwegian MedTech  company based in Oslo with the aim to contribute to fight
major threats to human health, namely; the Emergence of Antimicrobial Resistance
(AMR), Biofilm Infections in Chronic Wounds and Spread of viruses. For more
information about SoftOx please visit www.soft-ox.com
  
About Medical Technology Enterprise Consortium
MTEC is a biomedical technology consortium collaborating with multiple
government agencies under a 10-year renewable Other Transactional Agreement with
the U.S. Army Medical Research and Development Command.  To find out more about
MTEC, visit www.mtec-sc.org.